Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

导出原文传递

翻译打印收藏纠错

作者： Lyons,R.M. ^[1] ; Marek,B.J. ^[2] ; Paley,C. ^[3] ; Esposito,J. ^[4] ; Garbo,L. ^[5] ; DiBella,N. ^[6] ; Garcia-Manero,G.

作者单位： Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States ^[1] University of Texas, MD Anderson Cancer Center, Houston, TX, United States ^[2] US Oncology, The Woodlands, TX, United States, Texas Oncology-South Texas Cancer Center, McAllen ^[3] US Oncology, The Woodlands, TX, United States, New York Oncology Hematology, P.C., Albany, NY ^[4] Cancer Care Centers of South Texas, San Antonio, TX, United States, US Oncology, The Woodlands, TX ^[5] US Oncology, The Woodlands, TX, United States, Rocky Mountain Cancer Centers, Aurora, CO, United ^[6]

关键词 Chelation Ferritin Iron overload Leukemia Myelodysplastic syndrome Survival

发布时间 2014-04-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交